Ondine Biomedical Inc Common Share (OBI)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
9.50p
Buy
10.00p
0.00p (+0.00%)
Prices updated at 17 Dec 2025, 12:51 GMT
| Prices minimum 15 mins delay
Prices in GBX
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 1m | 2m | |
| 703,000 | 1m | |
| -15m | -19m | |
| -1,230.67 | -948.95 | |
| -14m | -19m | |
| -14m | -18m | |
| Sales, General and administrative | 10m | 11m |
| Interest expenses | 38,000 | 47,000 |
| Provision for income taxes | - | - |
| Operating expenses | 16m | 21m |
| Income before taxes | -14m | -19m |
| Net income available to common shareholders | -14m | -19m |
| -0.07 | -0.07 | |
| Net interest income | 204,000 | -15,000 |
| Advertising and promotion | - | - |
| Net investment income, net | -141,000 | 39,000 |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.07 | -0.07 |
| Free cash flow per share | -0.0498 | -0.0317 |
| Book value/share | 0.0108 | - |
| Debt equity ratio | 0.076259 | - |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 5m | 12m |
| Current liabilities | 3m | 6m |
| Total capital | 2m | 7m |
| Total debt | 541,000 | 168,000 |
| Total equity | 2m | 7m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 6m | 13m |
| Total liabilities | - | - |
| Cash and cash equivalents | 3m | 10m |
| Common stock | 227m | 404m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 13m | 3m |
| Cash dividends paid | - | - |
| -14m | -15m | |
| Investments (gains) losses | -177,000 | -10,000 |
| 3m | 10m | |
| Net income | - | - |
| -14m | -15m | |
| -177,000 | -10,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
